I-Sep
i-SEP is a French MedTech company that develops and commercializes same™, a CE-marked intraoperative autotransfusion device that uses patented tangential filtration to simultaneously recover and retransfuse both red blood cells and platelets during hemorrhagic surgery, sold directly to cardiac surgery hospitals in Europe.
- Company typePrivate
- Founded2015
- HeadquartersNantes, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
I-Sep firmographics
Firmographics- Name
- I-Sep
- Legal name
- i-SEP
- Website
- https://i-sep.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- i-SEP is a French MedTech company that develops and commercializes same™, a CE-marked intraoperative autotransfusion device that uses patented tangential filtration to simultaneously recover and retransfuse both red blood cells and platelets during hemorrhagic surgery, sold directly to cardiac surgery hospitals in Europe.
- Ownership category
- akta.pro rank
I-Sep industry classification
Industry- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)
- akta.pro secondary industry
- Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)
Keywords
Where I-Sep is headquartered
LocationHeadquarters
- HQ city
- Nantes
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
I-Sep business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical device sales (same™): i-SEP generates revenue through the sale and commercialization of its same™ intraoperative autotransfusion medical device system to hospitals and clinics across Europe. The device is sold directly to hospitals as a capital medical device with associated consumables kits. Following CE marking in 2022 under MDR 2017/745, commercial sales began in European markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical device (capital equipment + consumables) |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
I-Sep product offering
Product offeringCore offering
I-Sep develops, manufactures and commercializes the same™ intraoperative autotransfusion (IOCS) medical device for use during hemorrhagic or high-risk surgery. The system uses patented tangential filtration technology to simultaneously recover and wash both red blood cells and platelets from a patient's own shed blood, then retransfuse up to 630 mL back to the patient. The device is sold as a capital system plus per-procedure consumable kits directly to hospitals performing cardiac, vascular, trauma, orthopedic, transplant and neurosurgery.
Product overview
i-SEP offers a unified product portfolio centered on its patented same™ technology — a next-generation intraoperative autotransfusion system that recovers and retransfuses both the patient's red blood cells and platelets during hemorrhagic surgery. The same™ device represents the company's sole product offering, addressing a critical gap in traditional cell salvage systems that only preserve red blood cells. By enabling comprehensive autotransfusion (platelets + red blood cells), same™ provides an alternative or complement to allogenic blood transfusions, improving Patient Blood Management outcomes while reducing healthcare costs.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- 86% red blood cells recovered; 52% platelets recovered; 42% stable hematocrit concentration; 84% platelet functionality
- +5 more outcomes
Companies that use I-Sep
Customer profileNamed customers9 records
Segments2 records
Ideal customer profiles2 records
I-Sep technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature4 records
I-Sep partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered key, core and supporting.
- HemoSonicskeyStrategic co-marketing partnership for joint symposiums at major congresses. At NATA Congress 2024 in Munich, i-SEP and HemoSonics co-hosted a symposium on Patient Blood Management in cardiac surgery and obstetrics, combining i-SEP's same™ autotransfusion (platelets + RBC) with HemoSonics' Quantra® and qLabs® FIB coagulation monitoring solutions. Speakers included Aryeh Shander, Anne-Sophie Ducloy-Bouthors, and Dr. Gösta Lotz.
- CHU de Nantes (Nantes University Hospital)coreFirst hospital to adopt same™ in Europe. The anesthesia team led by Dr. Jean-Christophe Rigal and cardiac surgery team led by Prof. Jean-Christian Roussel and Prof. Bertrand Rozec served as clinical development partners. Featured on France TV's Le Mag de la Santé. Dr. Rozec presented at NATA Congress 2024. Part of the Nantes healthcare ecosystem including Atlanpole Biotherapies.
- CHU de Rennes (Rennes University Hospital)keyCoordinating center for the i-TRANSEP first-in-human clinical study on 50 cardiothoracic surgery patients. Dr. Alexandre Mansour led the study and presented results at EUMS 2023 conference and published in Anesthesiology journal 2023.
- CHU de Lille (Lille University Hospital)key15th center in France to adopt same™ technology in cardiac surgery in 2025. Led by anesthesia team (Emmanuel Robin, Olivier Joulin, Moussa Mouhamed) and cardiac surgery team (André Vincentelli). Their innovation project ranked #1 in September 2024.
- Hôpital Européen Georges Pompidou (Paris)keyClinical trial site for the i-TRANSEP study. The pharmacy team, in partnership with RWEALITY and i-SEP, developed the Organizational and Budget Impact Model (OBIM) published in 2024, demonstrating cost savings of €44,601 annually per hospital.
- Hôpitaux Universitaires de Genève (HUG)keyTesting same™ in cardiology operating rooms. Featured during World Blood Donor Day for potentially halving hemoglobin needs by recovering the patient's own blood components. Represents international expansion of the technology in Europe.
- RWEALITYsupportingPartnered with i-SEP and the pharmacy team at Georges Pompidou Hospital to develop the Organizational and Budget Impact Model (OBIM), published in 2024, quantifying the medico-economic benefits of same™ for hospitals.
- Stago BioCaresupportingCo-exhibited at the J.E.P.U. Anesthesia & Intensive Care Congress alongside Stago BioCare. Both companies serve the anesthesia and transfusion medicine space, with complementary product offerings for blood management.
- Atlanpole BiotherapiessupportingNantes-based healthcare innovation cluster that supports the regional healthcare ecosystem. Highlighted as part of the collaborative ecosystem including hospitals, research laboratories, and support organizations that fosters innovation in the Nantes region.
- Établissement Français du Sang (EFS - French National Blood Bank)supportingConducted in-vitro evaluation of i-SEP's first working prototype in 2017 as part of the product development and validation process.
- Oniris Veterinary SchoolsupportingConducted in-vivo evaluation of i-SEP's first working prototype in 2017 as part of preclinical validation before clinical trials.
- Business France / French HealthcaresupportingBusiness France North America and French Healthcare organization highlighted i-SEP's same™ technology internationally as an innovative French healthcare solution, supporting export and international visibility.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
I-Sep competitors and assessment
Company assessmentBroad incumbents
- Terumo BCT: Terumo BCT is the global leader in blood component collection and processing (apheresis, platelet and plasma collection). Operates broadly across transfusion medicine rather than intraoperative cell salvage, but its platelet-handling expertise makes it a strategically relevant adjacent player to i-SEP's platelet-recovery focus.
- Fresenius Kabi: Fresenius Kabi supplies blood collection/processing sets, autotransfusion disposables, and blood-bank products across hospital transfusion workflows. Overlaps with i-SEP on transfusion-medicine customers; also a relevant employer pedigree (i-SEP's Stéphane Chollet trained at Macopharma, a related blood-management group).
- Medtronic (legacy Blood Management business): Medtronic historically sold the Affinity and related cardiotomy/cell-salvation products for cardiac surgery before exiting parts of the portfolio. Operates broadly in cardiac surgery equipment rather than specializing in cell salvage, but overlaps on the same surgical use case and customer base as i-SEP.
- B. Braun (Aesculap / B. Braun Avitum): B. Braun supplies autotransfusion devices (e.g., the previous OrthoPAT / CatSmart lines) and broader blood-management consumables to hospitals. Broad incumbent with overlapping cardiac-surgery and transfusion-medicine customers, though cell salvage is not its primary focus.
Others
- Stago: Stago is a specialist in hemostasis and thrombosis diagnostics, including transfusion-medicine-adjacent coagulation testing. Co-exhibits with i-SEP at anesthesia congresses (J.E.P.U.); complementary (not competing) blood-management workflow player.
- HemoSonics: HemoSonics makes Quantra® and qLabs® FIB point-of-care coagulation monitoring, used alongside cell salvage for Patient Blood Management. Active co-marketing partner of i-SEP at NATA, addressing adjacent (not competitive) stages of the cardiac-surgery blood-management workflow.
Direct peers
- Haemonetics: Haemonetics is the global market leader in intraoperative cell salvage with the Cell Saver Elite+ and配套 consumables, directly competing with i-SEP in hospital autotransfusion workflows. Same target customer (perfusionists, cardiac surgeons, anesthesiologists) and same single-recovery limitation (RBC only).
- LivaNova: LivaNova (via the legacy Sorin Group) sells the Cell Saver system for intraoperative cell salvage during cardiac and major surgery. Directly competes with i-SEP's same™ device in the same hospital departments, but only recovers red blood cells — not platelets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
I-Sep social profiles
Digital presenceI-Sep compliance and trust
Trust signalCompliance2 records
I-Sep financial estimates
Financial estimateRevenue estimate
Valuation estimate
I-Sep leadership team
Management profileNumber of profiles
I-Sep funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
I-Sep M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about I-Sep
What does I-Sep do?
I-Sep develops, manufactures and commercializes the same™ intraoperative autotransfusion (IOCS) medical device for use during hemorrhagic or high-risk surgery. The system uses patented tangential filtration technology to simultaneously recover and wash both red blood cells and platelets from a patient's own shed blood, then retransfuse up to 630 mL back to the patient. The device is sold as a capital system plus per-procedure consumable kits directly to hospitals performing cardiac, vascular, trauma, orthopedic, transplant and neurosurgery.
Is I-Sep a public or private company?
I-Sep is a private company. It is currently operating.
When was I-Sep founded?
I-Sep was founded in 2015. It employs 11 to 50 people.
Where is I-Sep based?
I-Sep is headquartered in Nantes, France, in the Europe region.
How does I-Sep make money?
One revenue line is on record: medical device sales (same™).
Who are I-Sep's main competitors?
Broad incumbents on record are Terumo BCT, Fresenius Kabi, Medtronic (legacy Blood Management business) and B. Braun (Aesculap / B. Braun Avitum). Others are Stago and HemoSonics. Direct peers are Haemonetics and LivaNova.
Does I-Sep have an API?
No public API is recorded for I-Sep.
What industry is I-Sep in?
Its primary akta.pro industry code is HLAHAAAH, Blood Bank, Transfusion Medicine & Immunohematology, with a secondary code of HLAFAMAG, Transfusion Medicine & Immunohematology (Blood Bank). Its NAICS code is 339112 and its SIC code is 3841.